Scapho 150mg indicated for the treatment of patients with Plaque Psoriasis.
Scapho 150mg indicated for the treatment of patients withPsoriatic arthritis
Scapho 150mg indicated for the treatment of patients withAnkylosing spondylitis.
150mg in 1 vial
Scapho 150mg is a type of immunosuppressant medicationswhichreduces the effects of a chemical substance in the body which can cause inflammation.
Scapho 150mg is needed to cure moderate to severe plaque psoriasis (raised, silvery flaking of the skin) in adults.
Mechanism of action
Human IgG1 monoclonal antibody which selectively joins to and negate the proinflammatory cytokine interleukin 17A (IL-17A)
IL-17A is a normallyappearing cytokine which is involved in normal inflammatory and immune responses and plays a key role in the pathogenesis of plaque psoriasis
Plaque Psoriasis :
Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
A dose of 150 mg may be acceptable for some patients
Psoriatic Arthritis :
Indicated for adults with active psoriatic arthritis
Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without loading dose administrated 150 mg SC q4wk.
Considera dosage of 300 mg,If a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.
Ankylosing Spondylitis :
Given with or without a loading dosage by SC injection
Scapho with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without a loading dose is administrated150 mg SC q4wk
• URT infection
• Oral herpes
• Rhinorrhoea .
• Scapho may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
• May infuriate Crohn disease
• Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment
• Start with anti-TB therapy before to initiation of scapho in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed